NASDAQ:AMPH - Amphastar Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $22.00
  • Forecasted Upside: 25.57 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$17.52
▲ +0.31 (1.80%)
1 month | 3 months | 12 months
Get New Amphastar Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AMPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AMPH

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$22.00
▲ +25.57% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Amphastar Pharmaceuticals in the last 3 months. The average price target is $22.00, with a high forecast of $24.00 and a low forecast of $21.00. The average price target represents a 25.57% upside from the last price of $17.52.
Hold
The current consensus among 4 investment analysts is to hold stock in Amphastar Pharmaceuticals. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/14/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/13/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/12/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/10/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/8/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/7/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/5/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/7/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/8/2021Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$21.00High
i
10/5/2020Northland SecuritiesUpgradeMarket Perform ➝ Outperform$24.00High
i
Rating by Tim Chiang at Northland Securities
8/7/2020Northland SecuritiesReiterated RatingHold$23.00High
i
Rating by Tim Chiang at Northland Securities
7/9/2020Northland SecuritiesDowngradeOutperform ➝ Market Perform$23.00High
i
Rating by Tim Chiang at Northland Securities
6/10/2020Needham & Company LLCReiterated RatingHoldMedium
i
6/8/2020Northland SecuritiesReiterated RatingBuy$23.00Medium
i
Rating by Tim Chiang at Northland Securities
5/14/2020Northland SecuritiesReiterated RatingBuy$23.00High
i
5/11/2020BMO Capital MarketsBoost Price TargetMarket Perform$20.00 ➝ $21.00High
i
5/7/2020Northland SecuritiesReiterated RatingBuyMedium
i
5/1/2020Northland SecuritiesInitiated CoverageOutperform$23.00Low
i
4/27/2020Needham & Company LLCReiterated RatingHoldLow
i
1/29/2020Needham & Company LLCReiterated RatingHoldHigh
i
6/6/2019Wells Fargo & CompanySet Price TargetBuy$29.00Low
i
Rating by David Maris at Wells Fargo & Company
5/10/2019Wells Fargo & CompanyReiterated RatingBuyHigh
i
Rating by David Maris at Wells Fargo & Company
3/13/2019Needham & Company LLCDowngradeBuy ➝ Hold$22.20High
i
Rating by Serge Belanger at Needham & Company LLC
3/13/2019Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$24.00 ➝ $23.00High
i
11/14/2018Jefferies Financial GroupReiterated RatingBuy$26.00Medium
i
11/9/2018Needham & Company LLCSet Price TargetBuy$25.00N/A
i
Rating by Serge Belanger at Needham & Company LLC
11/9/2018Wells Fargo & CompanyReiterated RatingBuyHigh
i
8/10/2018Needham & Company LLCLower Price TargetBuy$24.00 ➝ $22.00Low
i
3/21/2018Wells Fargo & CompanyReiterated RatingBuyMedium
i
Rating by David Maris at Wells Fargo & Company
3/13/2018BMO Capital MarketsReiterated RatingMarket Perform ➝ Market Perform$17.00 ➝ $19.00High
i
3/13/2018Needham & Company LLCReiterated RatingBuy ➝ Buy$23.00 ➝ $24.00High
i
1/30/2018Piper Jaffray CompaniesReiterated RatingBuy$26.00Medium
i
Rating by David Amsellem at Piper Jaffray Companies
12/1/2017Needham & Company LLCBoost Price TargetBuy$20.00 ➝ $23.00Medium
i
11/10/2017BMO Capital MarketsBoost Price TargetMarket Perform$16.00 ➝ $17.00N/A
i
11/9/2017Raymond JamesDowngradeOutperform ➝ Market Perform$18.00N/A
i
10/29/2017Jefferies Financial GroupSet Price TargetBuy$19.00N/A
i
10/22/2017Piper Jaffray CompaniesSet Price TargetBuy$19.00N/A
i
Rating by David Amsellem at Piper Jaffray Companies
9/27/2017Needham & Company LLCBoost Price TargetBuy ➝ Buy$18.00 ➝ $20.00Medium
i
9/17/2017Piper Jaffray CompaniesReiterated RatingBuy$19.00Low
i
Rating by David Amsellem at Piper Jaffray Companies
8/11/2017Jefferies Financial GroupReiterated RatingBuy$20.00 ➝ $19.00Low
i
Rating by David Steinberg at Jefferies Financial Group Inc.
8/9/2017Piper Jaffray CompaniesSet Price TargetBuy$19.00Medium
i
Rating by David Amsellem at Piper Jaffray Companies
7/31/2017BMO Capital MarketsReiterated RatingHold$16.00Low
i
7/29/2017Piper Jaffray CompaniesSet Price TargetBuy$20.00Low
i
Rating by David Amsellem at Piper Jaffray Companies
7/22/2017Wells Fargo & CompanyReiterated RatingBuyMedium
i
Rating by David Maris at Wells Fargo & Company
5/10/2017Jefferies Financial GroupLower Price TargetBuy$21.00 ➝ $20.00Medium
i
Rating by David Steinberg at Jefferies Financial Group Inc.
4/20/2017Jefferies Financial GroupSet Price TargetBuy$21.00Low
i
Rating by David Steinberg at Jefferies Financial Group Inc.
3/14/2017Jefferies Financial GroupSet Price TargetBuy$21.00High
i
Rating by David Steinberg at Jefferies Financial Group Inc.
3/14/2017Raymond JamesDowngradeStrong-Buy ➝ Outperform$21.00 ➝ $18.00High
i
3/14/2017Piper Jaffray CompaniesLower Price TargetOverweight$22.00 ➝ $20.00High
i
3/14/2017BMO Capital MarketsLower Price TargetMarket Perform$18.00 ➝ $16.00High
i
3/14/2017Needham & Company LLCLower Price TargetBuy$20.00 ➝ $18.00High
i
12/21/2016Wells Fargo & CompanyReiterated RatingOutperform$22.00 ➝ $29.00N/A
i
11/9/2016Jefferies Financial GroupSet Price TargetBuy$19.00 ➝ $21.00N/A
i
Rating by David Steinberg at Jefferies Financial Group Inc.
9/7/2016Piper Jaffray CompaniesReiterated RatingOverweight$22.00 ➝ $23.00N/A
i
8/11/2016Piper Jaffray CompaniesReiterated RatingOverweight$22.00N/A
i
8/9/2016Jefferies Financial GroupBoost Price TargetBuy$16.00 ➝ $19.00N/A
i
8/9/2016BMO Capital MarketsReiterated RatingHold$17.00N/A
i
8/9/2016Needham & Company LLCBoost Price TargetBuy$20.00 ➝ $22.00N/A
i
6/28/2016BMO Capital MarketsInitiated CoverageMarket Perform$17.00N/A
i
5/10/2016Needham & Company LLCLower Price TargetBuy$21.00 ➝ $20.00N/A
i
3/15/2016Raymond JamesLower Price Target$23.00 ➝ $18.00N/A
i
(Data available from 3/7/2016 forward)
Amphastar Pharmaceuticals logo
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; naloxone for opioid overdose; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; and Cortrosyn, a lyophilized powder use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; lidocaine jelly, a local anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection for newborn babies; atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate for emergency use in hospital settings; morphine injection; and lorazepam injection for surgery and medical procedures. In addition, it offers procainamide for documented ventricular arrhythmias; neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; medroxyprogesterone acetate injectable suspension for the prevention of pregnancy; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block, as well as recombinant human insulin API (active pharmaceutical ingredients) and porcine insulin API. Further, the company has a pipeline of 20 product candidates in various stages of development for various indications. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Read More

Today's Range

Now: $17.52
$17.12
$17.57

50 Day Range

MA: $18.48
$17.21
$19.26

52 Week Range

Now: $17.52
$12.32
$22.69

Volume

222,278 shs

Average Volume

212,539 shs

Market Capitalization

$832.27 million

P/E Ratio

125.14

Dividend Yield

N/A

Beta

0.87

Frequently Asked Questions

What sell-side analysts currently cover shares of Amphastar Pharmaceuticals?

The following Wall Street sell-side analysts have issued stock ratings on Amphastar Pharmaceuticals in the last twelve months: BMO Capital Markets, Needham & Company LLC, Northland Securities, TheStreet, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for AMPH.

What is the current price target for Amphastar Pharmaceuticals?

3 Wall Street analysts have set twelve-month price targets for Amphastar Pharmaceuticals in the last year. Their average twelve-month price target is $22.00, suggesting a possible upside of 25.6%. Northland Securities has the highest price target set, predicting AMPH will reach $24.00 in the next twelve months. BMO Capital Markets has the lowest price target set, forecasting a price of $21.00 for Amphastar Pharmaceuticals in the next year.
View the latest price targets for AMPH.

What is the current consensus analyst rating for Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals currently has 3 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in AMPH, but not buy more shares or sell existing shares.
View the latest ratings for AMPH.

What other companies compete with Amphastar Pharmaceuticals?

How do I contact Amphastar Pharmaceuticals' investor relations team?

Amphastar Pharmaceuticals' physical mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The company's listed phone number is 909-980-9484 and its investor relations email address is [email protected] The official website for Amphastar Pharmaceuticals is www.amphastar.com.